StockData
GoodRx Holdings, Inc. logo

GoodRx Holdings, Inc. (GDRX) stock

GDRXNasdaqServices-Computer Processing & Data PreparationFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 11/3045% below fair value
$3.02−0.34 (-10.12%)

Close on Nov 19, 2026Market cap $1.03BP/E 75.5Yield –

GoodRx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

GoodRx's free cash flow for the twelve months ending Jun 30, 2026 was $197.09M, up 4.0% year over year. For fiscal 2025 it was $164.38M, down 10.0% from the year before. The highest annual figure on record is $182.65M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$164.38M-10.0%
FY2024Dec 31, 2024$182.65M+33.1%
FY2023Dec 31, 2023$137.25M-3.9%
FY2022Dec 31, 2022$142.81M-18.0%
FY2021Dec 31, 2021$174.21M+57.2%
FY2020Dec 31, 2020$110.79M+35.3%
FY2019Dec 31, 2019$81.86M+84.2%
FY2018Dec 31, 2018$44.45M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$80.47M+63.6%
Q1 FY2026Mar 31, 2026$10.70M+15.4%
Q4 FY2025Dec 31, 2025$31.65M-29.0%
Q3 FY2025Sep 30, 2025$74.28M-14.1%
Q2 FY2025Jun 30, 2025$49.19M+421.5%
Q1 FY2025Mar 31, 2025$9.27M-78.0%
Q4 FY2024Dec 31, 2024$44.58M+188.4%
Q3 FY2024Sep 30, 2024$86.46M+43.9%
Q2 FY2024Jun 30, 2024$9.43M-68.1%
Q1 FY2024Mar 31, 2024$42.18M+31.2%
Q4 FY2023Dec 31, 2023$15.46M-51.3%
Q3 FY2023Sep 30, 2023$60.08M+81.6%
Q2 FY2023Jun 30, 2023$29.57M-40.4%
Q1 FY2023Mar 31, 2023$32.14M+13.2%
Q4 FY2022Dec 31, 2022$31.73M-35.3%
Q3 FY2022Sep 30, 2022$33.09M-30.9%
Q2 FY2022Jun 30, 2022$49.61M+43.5%
Q1 FY2022Mar 31, 2022$28.38M-33.6%
Q4 FY2021Dec 31, 2021$49.00M+391.1%
Q3 FY2021Sep 30, 2021$47.85M+155.0%
Q2 FY2021Jun 30, 2021$34.58M-6.9%
Q1 FY2021Mar 31, 2021$42.77M-4.8%
Q4 FY2020Dec 31, 2020$9.98M-38.0%
Q3 FY2020Sep 30, 2020$18.76M–
Q2 FY2020Jun 30, 2020$37.13M–
Q1 FY2020Mar 31, 2020$44.92M–
Q4 FY2019Dec 31, 2019$16.08M–

More GoodRx figures

See a number that looks wrong?